Long term responses with cetuximab therapy in glioblastoma multiforme

Cancer Biology and Therapy

Volumn 5, Issue 9, 2006, Pages 1242-1243

  Lustig, Robert ^a  

^a HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

Cetuximab; Glioblastoma; Monoclonal antibodies

Indexed keywords

BEVACIZUMAB; CETUXIMAB; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; IRINOTECAN; MAB 425; MONOCLONAL ANTIBODY; NITROSOUREA; RITUXIMAB; TEMOZOLOMIDE; TRASTUZUMAB;

ADJUVANT CHEMOTHERAPY; BLOOD BRAIN BARRIER; BRAIN TUMOR; CANCER GROWTH; CANCER RADIOTHERAPY; CANCER SURVIVAL; CLINICAL TRIAL; DOSE RESPONSE; DRUG RESPONSE; GLIOBLASTOMA; HUMAN; LONG TERM CARE; NOTE; PATIENT CARE;

EID: 33751090065     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.5.9.3420     Document Type: Note

References (6)

1. Walker MD, Green SB, Byar DP, Alexander E Jr, Batzdorf U, Brooks WH, Hunt WE, MacCarty CS, Mahaley MS Jr, Mealey J Jr, Owens G, Ransohoff J 2nd, Robertson JT, Shapiro WR, Smith KR Jr, Wilson CB, Strike TA. Randomized comparisons of radiotherapy and nitrosoureas for the treatment of malignant glioma after surgery. N Eng J Med 1980; 303:1323-9.
2. Stupp R, Mason WP, van den Bent MJ, Weller M et al, Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N Eng J Med 2005; 352:987-96.
3. The Quest for a Magic Bullet. Time Magazine 1980; Aug 11.
4. Golden F. Of Mice and Men: Don't Blame the Rodents. Time Magazine 1998; May 18.
5. Quang TS, Brady LW, Radioimmunotherapy as a Novel Treatment regimen: 125I Labeled Monoclonal Antibody 425 in the Treatment of High-Grade Gliomas. Int J Radiat Oncol Biol Phys 2004; 58:972-5.
6. Combs SE, Heeger S, Haselmann R, Edler L, Debus J, Schulz-Ertner D. Treatment of Primary Glioblastoma with Cetuximab, radiotherapy and Temozolomide(GERT) Phase I/II Trial: Study protocol. BMC Cancer 2006; 6:133